PW
Walker, Paul Richard
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research |  | 2024 | 68 | 50 | ||
| Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | | 2024 | 43 | 9 | ||
| Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming | International journal of molecular sciences | | 2024 | 13 | 0 | ||
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | 2024 | 51 | 13 | ||
| Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | Clinical and Experimental Medicine | | 2024 | 28 | 15 | ||
| How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy | OpenNano | | 2023 | 19 | 7 | ||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | 2023 | 236 | 40 | ||
| Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition | Neuro-oncology | | 2022 | 238 | 84 | ||
| Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors | Pharmaceutics | | 2022 | 201 | 56 | ||
| An update on actively targeted liposomes in advanced drug delivery to glioma | International journal of pharmaceutics |  | 2021 | 125 | 1 | ||
| Glioma-Derived Extracellular Vesicles - Far More Than Local Mediators | Frontiers in immunology | | 2021 | 161 | 80 | ||
| Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma | Journal for immunotherapy of cancer | | 2021 | 181 | 69 | ||
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | | 2021 | 184 | 42 | ||
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | | 2021 | 284 | 176 | ||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | 2020 | 424 | 258 | ||
| Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer | Journal of Controlled Release | | 2020 | 212 | 109 | ||
| Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | | 2020 | 140 | 142 | ||
| Harnessing Microglia and Macrophages for the Treatment of Glioblastoma | Frontiers in Pharmacology | | 2019 | 398 | 211 | ||
| Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine | JCI Insight | | 2019 | 254 | 3 | ||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | 2019 | 739 | 355 | ||
| Peptides as cancer vaccines | Current Opinion in Pharmacology | | 2019 | 366 | 4 | ||
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | | 2018 | 366 | 1 | ||
| Let there be oxygen and T cells | Journal of Clinical Investigation | | 2018 | 347 | 154 | ||
| Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines | Cellular and Molecular Life Sciences | | 2018 | 346 | 141 | ||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | 2018 | 595 | 263 | ||
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 369 | 0 | |||
| Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes | EMBO Reports | | 2017 | 533 | 4 | ||
| ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | | 2017 | 557 | 10 | ||
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | 2016 | 459 | 382 | ||
| Cell-penetrating peptides-the Swiss Army knife of cancer vaccines | Oncoimmunology | | 2016 | 585 | 263 | ||
| Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes | PloS one | | 2016 | 521 | 191 | ||
| Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? | OncoImmunology | | 2016 | 433 | 235 | ||
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | | 2016 | 548 | 588 | ||
| Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants | Molecular therapy | | 2016 | 612 | 259 | ||
| Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells | European Journal of Immunology | | 2015 | 493 | 7 | ||
| Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity | Cancer research | | 2015 | 571 | 10 | ||
| Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 522 | 0 | |||
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | | 2015 | 444 | 162 | ||
| Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | | 2014 | 1 194 | 558 | ||
| Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours | PloS one | | 2013 | 647 | 298 | ||
| The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity | Journal of neuroinflammation | | 2013 | 590 | 330 | ||
| Getting by with a little help from the right CD4+ T cells | Oncoimmunology | | 2013 | 520 | 205 | ||
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy |  | 2013 | 492 | 0 | ||
| Macrophages and Microglia in Brain Malignancies | Tumor Microenvironment and Myelomonocytic Cells | | 2012 | 489 | 576 | ||
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | | 2012 | 631 | 1 264 | ||
| Oncology ESAB 2011 | | 2011 | 597 | 10 | |||
| Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development | Cancer research | | 2010 | 548 | 3 | ||
| T-cell immunotherapy for malignant glioma: toward a combined approach | Current opinion in oncology | | 2010 | 618 | 2 | ||
| Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes | GLIA | | 2008 | 583 | 11 |
